HONG KONG SAR - Media OutReach Newswire – 12 November 2024 - Immuno Cure BioTech (" Immuno Cure "), a clinical-stage ...

Nigeria, South Africa, Zambia, Zimbabwe, Tanzania, Uganda, Kenya, and Mozambique have begun locally-led HIV vaccine research ...

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development ...

The project, aptly named BRILLIANT, an acronym for “Bringing Innovation to Clinical and Laboratory Research to End HIV in ...

As the science stands, the vast majority of the roughly eight million people in South Africa living with HIV will have to get ...

The federal government yesterday formally announced the commencement of the HIV Vaccine Innovation, Science, and Technology ...

Private insurance companies in the U.S. aren’t required to cover the cost of the mpox vaccine, which costs $270 a dose.

The epidemic of sexually transmitted infections (STIs) in the United States appears to be cooling off after more than two ...

The study reconfirms longstanding priorities for vaccine research and development, including HIV, malaria and tuberculosis – ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

The World Health Organisation has spotlighted 17 pathogens critical for vaccine development. Urgent vaccines are needed against diseases like malaria, HIV, and tuberculosis, etc.

They found success in an unlikely source -- ... July 2, 2024 — A major challenge in developing a vaccine for HIV is that the virus mutates fast -- very fast. Although a person initially becomes ...